The Food and Drug Administration (FDA) told the maker of Purell to discontinue marketing campaigns that includes claims for avoiding flu and ebola, according to an article on The New York Times website.
The campaigns also claim the product can prevent spread of MRSA and norovirus.
The FDA told Gojo Industries that its claims that Purell could reduce the potential for infection or prevent illnesses violated the Federal Food, Drug and Cosmetic Act.
The agency said it was reclassifying Purell as an unapproved drug, rather than an over-the-counter product.
Seeking Standards for Microbial Loads in Healthcare Facilities
UCR Health Unveils Plans for Major Expansion
High-Performance Windows Support Safety at UW Medicine's New Behavioral Health Center
Central Maine Healthcare Dealing with IT System Outage
Kaiser Permanente Opens Newly Expanded Everett Medical Center